Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195

Overview of attention for article published in Leukemia, February 2003

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 1 news outlet

patent: 7 patents

Readers on

mendeley: 48 Mendeley

So far, Altmetric has seen 7 patents that reference this research output.

LIPID NANOPARTICLE LOADED WITH ANTITUMORAL AGENT AND FUNCTIONNALIZED TO TARGET…

Application WO-2025202213-A1

World Intellectual Property Organisation (WIPO)

02 Oct 2025

NON-GLYCOSYLATED ANTI-TENASCIN ANTIBODY

Application WO-2017178569-A1

World Intellectual Property Organisation (WIPO)

19 Oct 2017

TARGETING OF BONE MARROW NEOVASCULATURE

Application EP-2947096-A1

European Patent Office

25 Nov 2015

Assays for anti-drug antibodies in the presence of abundant endogenous protein…

Grant US-8877687-B2

United States of America

04 Nov 2014

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 3 additional patents.